Analyze Diet
Virus genes2002; 25(2); 159-167; doi: 10.1023/a:1020109801925

Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus.

Abstract: Equine arteritis virus (EAV) is the causative agent of the equine viral arteritis. It is a small RNA virus with a linear, non-segmented plus RNA genome. EAV is a member of the Arteriviridae family that includes porcine reproductive and respiratory syndrome virus (PRSSV), simian haemorrhagic fever virus (SHFV) and lactate dehydrogenase virus (LDV). The viral transmission is via respiratory and reproductive routes. Clinical signs in horses vary, and severe infection can lead to abortions in pregnant mares or neonatal foal death. The aim of this study was to investigate the development of the immune response in horses after immunization with a DNA vaccine harbouring and expressing EAV Open Reading Frames (ORF) 2, 5, and 7, in combination with equine interleukin 2 (eqIL2). Three boosters followed the basic immunization in two-week intervals. Each immunization was a combination of gene gun and intramuscular injection. All horses developed a high titer of neutralizing antibodies after basic immunization within 2 weeks. Remarkably, this immune response was found to be independent of the age of animals. The youngest horse was six-years old, and the oldest twenty-two years old. A remarkable difference in the immune response between the young and old were not observed. The duration of immunity was investigated during a period of one year. After 12 months, neutralizing antibodies were still detectable in all the vaccinated horses.
Publication Date: 2002-11-07 PubMed ID: 12418451DOI: 10.1023/a:1020109801925Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research examines the immune response in horses after being vaccinated against the equine arteritis virus (EAV) using DNA. The study found that the horses developed high levels of neutralizing antibodies within two weeks, regardless of the animal’s age, and the immunity provided lasted for at least a year.

Introduction

  • EAV is a small RNA virus that causes equine viral arteritis, a disease that can cause severe infections and potentially abortions in pregnant mares or neonatal foal death.
  • Transmission of this virus is through the respiratory and reproductive routes, meaning it can easily spread amongst horse populations.

Objective of the Study

  • This research aimed to investigate the horse immune response after vaccination using a DNA vaccine expressing EAV Open Reading Frames (ORF) 2, 5, and 7 alongside equine interleukin 2 (eqIL2).
  • The scientists wanted to see if this vaccine could produce a sufficient immune response to protect against EAV, how quickly this response occurred, if it was influenced by the age of the horse, and how long the immunity lasted.

Methodology

  • After the initial vaccination, there were three booster shots given at two-week intervals.
  • Both gene gun and intramuscular injection techniques were used for each vaccination.

Results and Findings

  • All horses developed high levels of neutralizing antibodies within two weeks of the initial vaccination, showing a rapid immune response.
  • The age of the horse did not impact the immune response, as both young and old horses had a similar antibody response.
  • The immunity provided by the vaccine was found to last for at least a year, as neutralizing antibodies were still detected in all vaccinated horses 12 months later.

Conclusion

  • The DNA vaccine was effective in stimulating a strong, rapid immune response in horses of varying ages against the EAV.
  • This immune response was also long-lasting, providing immunity for at least a year after vaccination.
  • These results suggest that this DNA vaccine could be an effective strategy for protecting horse populations against EAV.

Cite This Article

APA
Giese M, Bahr U, Jakob NJ, Kehm R, Handermann M, Müller H, Vahlenkamp TH, Spiess C, Schneider TH, Schusse G, Darai G. (2002). Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus. Virus Genes, 25(2), 159-167. https://doi.org/10.1023/a:1020109801925

Publication

ISSN: 0920-8569
NlmUniqueID: 8803967
Country: United States
Language: English
Volume: 25
Issue: 2
Pages: 159-167

Researcher Affiliations

Giese, M
  • Boehringer Ingelheim Animal Health, Ingelheim am Rhein, Germany.
Bahr, U
    Jakob, N J
      Kehm, R
        Handermann, M
          Müller, H
            Vahlenkamp, T H
              Spiess, C
                Schneider, T H
                  Schusse, G
                    Darai, G

                      MeSH Terms

                      • Animals
                      • Antibodies, Viral / blood
                      • Arterivirus Infections / prevention & control
                      • Arterivirus Infections / veterinary
                      • Arterivirus Infections / virology
                      • Equartevirus / immunology
                      • Horse Diseases / prevention & control
                      • Horse Diseases / virology
                      • Horses
                      • Interleukin-2 / genetics
                      • Interleukin-2 / immunology
                      • Neutralization Tests
                      • Open Reading Frames / genetics
                      • Open Reading Frames / immunology
                      • Plasmids
                      • Vaccination
                      • Vaccines, DNA / administration & dosage
                      • Vaccines, DNA / immunology
                      • Viral Vaccines / administration & dosage
                      • Viral Vaccines / immunology

                      References

                      This article includes 23 references
                      1. J Gen Virol. 1999 Aug;80 ( Pt 8):1949-58
                        pubmed: 10466790
                      2. Vaccine. 1994 Dec;12(16):1503-9
                        pubmed: 7879414
                      3. Science. 1990 Mar 23;247(4949 Pt 1):1465-8
                        pubmed: 1690918
                      4. Nucleic Acids Res. 1997 Dec 15;25(24):4876-82
                        pubmed: 9396791
                      5. Virus Genes. 1998;17(3):219-32
                        pubmed: 9926398
                      6. Virus Genes. 2001 Mar;22(2):187-99
                        pubmed: 11324756
                      7. Virus Res. 1991 Mar;19(1):115-26
                        pubmed: 1651032
                      8. Hum Mol Genet. 1992 Sep;1(6):363-9
                        pubmed: 1301910
                      9. Vaccine. 1997 Jan;15(1):71-8
                        pubmed: 9041669
                      10. Biochemistry. 1974 Jun 4;13(12):2633-7
                        pubmed: 4831907
                      11. Vaccine. 1997 Jun;15(8):788-91
                        pubmed: 9234514
                      12. Virus Res. 1989 Jan;12(1):43-51
                        pubmed: 2541581
                      13. Br Vet J. 1992 May-Jun;148(3):181-97
                        pubmed: 1319787
                      14. J Virol. 1991 Jun;65(6):2910-20
                        pubmed: 1851863
                      15. J Exp Med. 1997 Nov 3;186(9):1481-6
                        pubmed: 9348305
                      16. DNA Cell Biol. 1993 Nov;12(9):771-6
                        pubmed: 7692877
                      17. Vet Q. 1996 Sep;18(3):95-9
                        pubmed: 8903141
                      18. Vet Clin North Am Equine Pract. 1993 Aug;9(2):295-309
                        pubmed: 8395325
                      19. J Gen Virol. 1997 Sep;78 ( Pt 9):2139-46
                        pubmed: 9291999
                      20. J Virol. 1999 Aug;73(8):6335-45
                        pubmed: 10400725
                      21. Annu Rev Microbiol. 1997;51:151-78
                        pubmed: 9343347
                      22. Virology. 2000 Mar 1;268(1):49-55
                        pubmed: 10683326
                      23. Virology. 1995 Jun 1;209(2):569-79
                        pubmed: 7778289